Lucentis and Acute coronary syndrome - a phase IV clinical study of FDA data

Summary:

Acute coronary syndrome is reported as a side effect among people who take Lucentis (ranibizumab), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Avastin, and have Age-related macular degeneration.

The phase IV clinical study analyzes which people have Acute coronary syndrome when taking Lucentis. It is created by eHealthMe based on reports of 25,577 people who have side effects when taking Lucentis from the FDA, and is updated regularly.

What is Lucentis?

Lucentis has active ingredients of ranibizumab. It is often used in macular degeneration. eHealthMe is studying from 25,647 Lucentis users. Check the latest studies of Lucentis.

What is Acute coronary syndrome?

Acute coronary syndrome (acute chest pain and other symptoms that happen because the heart does not get blood) is found to be associated with 736 drugs and 1,078 conditions by eHealthMe. Check the latest studies of Acute coronary syndrome.

On Jul, 12, 2026

25,577 people reported to have side effects when taking Lucentis.
Among them, 25 people (0.1%) have Acute coronary syndrome.

Could Lucentis cause Acute coronary syndrome?

Among these 25 people:

How long have people been on Lucentis when they have Acute coronary syndrome? *

What is the gender of people who have Acute coronary syndrome when taking Lucentis? *

female: 52 %
male: 48 %

What is the age of people who have Acute coronary syndrome when taking Lucentis? *

What are other drugs people take besides Lucentis? *

What are other side effects people have besides Acute coronary syndrome? *

Gastrointestinal Haemorrhage (bleeding gastrointestinal tract): 2 people, 8.00%
Acute Myocardial Infarction (acute heart attack): 2 people, 8.00%
Coronary Heart Disease (narrowing or blockage of the coronary arteries): 2 people, 8.00%
Death: 2 people, 8.00%
Dyspnea (difficult or laboured breathing): 2 people, 8.00%
Heart Attack: 2 people, 8.00%
Chest Pain: 2 people, 8.00%
Blood Pressure Systolic Increased: 2 people, 8.00%
Blood Urea Increased: 1 person, 4.00%
Cardiac Disorder: 1 person, 4.00%

What are the existing conditions these people have? *

Diabetic Retinal Oedema (excessive build-up of fluid in the retina due to diabetes): 4 people, 16.00%
Age-Related Macular Degeneration: 4 people, 16.00%
Maculopathy (a condition or disease of the macula, the small spot in the retina where vision is keenest): 3 people, 12.00%
High Blood Pressure: 2 people, 8.00%
Visual Acuity Reduced (reduced clearness of vision): 1 person, 4.00%
Retinal Vessel Occlusion (a blockage in one of the small arteries): 1 person, 4.00%
Glaucoma (increased fluid pressure in the eye with vision loss): 1 person, 4.00%

* Approximation only. Some reports may have incomplete information.

Do you take Lucentis and have Acute coronary syndrome?

- Check whether Acute coronary syndrome is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lucentis:

Lucentis (25,647 reports)

Browse all side effects of Lucentis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Acute coronary syndrome:

Acute coronary syndrome (736 drugs)

Browse all the conditions that are associated with Acute coronary syndrome:

Acute coronary syndrome (1,078 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ranibizumab (the active ingredients of Lucentis) and Lucentis (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.